

Supplementary Materials

Suppl 1. Comparisons of baseline characteristics of SHNC patients by therapeutic modality types include NRT and RT.

	NRT for EC (N = 36)	RT for EC (N = 110)	P-value
Race			0.576
Black	8 (22.2%)	34 (30.9%)	
White	26 (72.2%)	68 (61.8%)	
Other	2 (5.6%)	8 (7.3%)	
Year of SHNC diagnosis			0.777
1975-1984	1 (2.8%)	7 (6.4%)	
1985-1994	11 (30.6%)	26 (23.6%)	
1995-2004	11 (30.6%)	32 (29.1%)	
≥2005	13 (36.1%)	45 (40.9%)	
Age of SHNC diagnosis			0.646
20-49	1 (2.8%)	6 (5.5%)	
50-74	27 (75.0%)	87 (79.1%)	
≥75	8 (22.2%)	17 (15.5%)	
Sex			0.226
Female	9 (25.0%)	41 (37.3%)	
Male	27 (75.0%)	69 (62.7%)	
Tumor stage of SHNC			0.357
Distant	4 (11.1%)	9 (8.2%)	
Localized	11 (30.6%)	21 (19.1%)	
Regional	15 (41.7%)	50 (45.5%)	
Unknown	6 (16.7%)	30 (27.3%)	
Tumor histology of SHNC			0.137
Adenocarcinoma	0 (0%)	1 (0.9%)	
Squamous carcinoma	32 (88.9%)	106 (96.4%)	

Others	4 (11.1%)	3 (2.7%)	
Tumor grade of SHNC			0.0442
Grade I/II	13 (36.1%)	57 (51.8%)	
Grade III/IV	14 (38.9%)	20 (18.2%)	
Unknown	9 (25.0%)	33 (30.0%)	
Tumor size of SHNC			0.803
<2cm	2 (5.6%)	5 (4.5%)	
≥2cm	6 (16.7%)	16 (14.5%)	
Unknown	28 (77.8%)	89 (80.9%)	
Chemotherapy of SHNC			0.527
No/Unknown	24 (66.7%)	80 (72.7%)	
Yes	12 (33.3%)	30 (27.3%)	
Surgery of SHNC			0.848
No Surgery	19 (52.8%)	61 (55.5%)	
Surgery performed	17 (47.2%)	49 (44.5%)	
Radiotherapy of SHNC			0.556
NRT	12 (33.3%)	44 (40.0%)	
RT	24 (66.7%)	66 (60.0%)	
Median age of SHNC diagnosis (IQR), years	67 (62.8-74.0)	65 (59.0-72.0)	0.105
Median year of SHNC diagnosis (IQR)	2001 (1991-2010.3)	2001.5 (1992-2012.8)	0.730
Median follow-up time of patients with SHNC (IQR), months	24.5 (8.5-62.3)	17 (5.3-32.0)	0.151

EC: esophageal cancer; SHNC: secondary head, and neck cancer; RT: radiation therapy; NRT: no radiation therapy; IQR: interquartile range.